uracil has been researched along with Benign Neoplasms in 223 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine and compare the ratio of uracil (U) to dihydrouracil (UH(2)) concentrations in plasma as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency." | 7.78 | Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency. ( Edwards, GL; Freeman, KG; Saba, CF; Schmiedt, CW, 2012) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "As all the anticancer agents, 5-FU leads to several toxicities." | 3.80 | Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. ( Malet-Martino, M; Martino, R, 2002) |
| "To determine and compare the ratio of uracil (U) to dihydrouracil (UH(2)) concentrations in plasma as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency." | 3.78 | Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency. ( Edwards, GL; Freeman, KG; Saba, CF; Schmiedt, CW, 2012) |
| "0%) had at least 1 adverse event leading to study discontinuation." | 2.90 | Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. ( Bebeau, P; Becerra, C; Rosen, L; Rudek, MA; Saif, MW; Shepard, DR; Sun, W; Winkler, R; Yamashita, F, 2019) |
| " A phase 1 study evaluated relative bioavailability of TAS-102 tablets compared with an oral solution containing equivalent amounts of FTD and TPI." | 2.84 | A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil. ( Becerra, CR; Mizuguchi, H; Patel, M; Von Hoff, D; Yoshida, K, 2017) |
| "Patients with advanced solid tumors (6 M/2 F; median age 58 years; PS 0-1) were enrolled on this study." | 2.82 | Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. ( Beumer, JH; Chu, E; Croft, M; Faulkner, T; Fawcett, P; Fiejdasz, J; Hague, J; Lee, JJ; Mason, S; Mizuguchi, H; Nugteren, J; Parise, RA; Pollice, L; Seraj, J; Strychor, S; Sun, W; Tedder, C; Yoshida, K, 2016) |
| " Major adverse events were neutropenia, leukopenia, anemia, and nausea." | 2.82 | Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors. ( Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T, 2016) |
| "This study was designed to determine the safety and optimal dosing of TAS-102, a novel oral combination of alphaalphaalpha-trifluorothymidine (FTD) and an inhibitor of thymidine phoshorylase, in patients with solid tumors." | 2.73 | Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. ( Abbruzzese, JL; Fukushima, M; Hoff, PM; Kopetz, S; Kuwata, K; Mita, A; Overman, MJ; Thomas, MB; Varadhachary, G; Wolff, RA; Xiong, H, 2008) |
| "The purpose of the current study was to determine the maximum tolerated dose, dose-limiting toxicities, pharmacokinetic profile, and recommended Phase II dose of oral administration of TAS-102, a novel nucleoside formed by the combination of alpha,alpha,alpha-trifluorothymidine (FTD) and a thymidine phosphorylase inhibitor (TPI: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione)." | 2.72 | Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. ( Abbruzzese, JL; Bogaard, K; Fukushima, M; Hoff, PM; Hong, DS; Kuwata, K; Lassere, Y; Mita, A, 2006) |
| " Individualized dosing for these patients can reduce the incidence of severe fluoropyrimidine-related toxicity." | 2.72 | Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options? ( Beijnen, JH; Cats, A; Gelderblom, H; Guchelaar, HJ; Henricks, LM; Knikman, JE, 2021) |
| "To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.71 | Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule. ( Cliatt, J; Grem, JL; Grollman, F; Guo, XD; Hamilton, JM; Harold, N; McQuigan, EA; Monahan, BP; Nguyen, D; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Takimoto, CH; Thomas, RR; Wilson, R, 2003) |
| "One patient with colorectal cancer experienced a partial response and 9 patients with non-small cell lung, colorectal and gastro-oesophageal junction carcinomas had disease stabilisation lasting 4-26 (median 6) cycles." | 2.71 | Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. ( Algazy, K; Giantonio, B; Hahn, S; Haller, DG; O'Dwyer, PJ; Redlinger, M; Stevenson, JP; Sun, W; Thorn, C; Vaughn, D; Veronese, ML; Whitehead, AS, 2004) |
| " The treatment plan consisted of weekly gemcitabine for three weeks with twice daily dosing of 5-FU and eniluracil for 21 days beginning on day one of gemcitabine." | 2.70 | Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy. ( Alberti, D; Arzoomanian, RZ; Bailey, H; Berlin, JD; Binger, K; Feierabend, C; Marrocha, R; Morgan-Meadows, S; Mulkerin, D; Thomas, JP; Volkman, J; Wilding, G, 2002) |
| "When eniluracil is given with 5-FU/LV, DPD inhibition appears to be influenced by schedule, and the time to recovery is much longer than has been observed with eniluracil given alone." | 2.70 | Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition. ( Grem, JL; Guo, XD; Harold, N; Keith, B; Quinn, M; Schuler, B; Shapiro, J; Zentko, S, 2002) |
| " To determine the bioequivalence of the combined eniluracil/5-FU dosing forms compared to the separate tablets, an analysis of variance on pharmacokinetic parameters reflecting eniluracil and 5-FU exposure was performed." | 2.69 | Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies. ( Cohen, D; Drengler, R; Ertel, VP; Hoffman, C; Hsieh, A; Hurwitz, HI; Magnum, S; Monroe, P; Ochoa, L; Petros, WP; Rowinsky, EK; Schwartz, G; Thomas, JP; Wilding, G, 2000) |
| "Patients received a single 24-hour infusion of 5-FU (2,300 mg/m(2) on day 2) with leucovorin (15 mg orally [PO] bid on days 1 through 3) to provide reference pharmacokinetic data." | 2.69 | Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors. ( Bi, DQ; Donavan, S; Grem, JL; Grollman, F; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Quinn, MG; Shapiro, J; Takimoto, CH; Zentko, S, 2000) |
| "Gemcitabine (Gemzar) is a nucleoside analog increasingly used in the treatment of a variety of solid tumors." | 2.69 | Gemcitabine and UFT plus oral calcium folinate: phase I study. ( Arlauskas, P; Ibrahim, D; Philip, PA; Shields, A; Zalupski, M, 1999) |
| "Since cancer is incurable in many patients, palliation of symptoms and quality-of-life issues are important aspects of therapy." | 2.69 | UFT/calcium folinate plus weekly paclitaxel for solid tumors. ( Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Mayer, F, 1999) |
| "Patients with advanced solid tumors refractory to standard therapy were enrolled at two institutions." | 2.69 | Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. ( Burris, HA; Diasio, R; Hohneker, J; Janisch, L; Khor, SP; Lucas, VS; Ratain, MJ; Schilsky, RL; Smetzer, L; Von Hoff, DD, 1998) |
| " Pharmacokinetic evaluation showed that single-dose UFT results in maximum plasma levels and an area under the concentration-time curve that increased with escalating UFT doses." | 2.68 | Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. ( Pazdur, R, 1997) |
| "Twelve patients completed the bioavailability and pharmacokinetic studies." | 2.68 | Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. ( Adjei, AA; Baker, SD; Donehower, RC; Doucette, M; Grochow, LB; Hohneker, JA; Khor, SP; Noe, DA; Rowinsky, EK; Sartorius, SE; Spector, T, 1996) |
| "All trials performed on type 2 diabetes, with duration ≥ 24 weeks, and comparing of DPP4i with placebo or active drugs were collected." | 2.66 | Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. ( Dicembrini, I; Mannucci, E; Monami, M; Montereggi, C; Nreu, B, 2020) |
| " This review summarizes the current state of knowledge of FIC with special regard to proposed pathogenetic models (coronary vasospasm, endothelium and cardiomyocytes damage, toxic metabolites, dihydropyrimidine dehydrogenase deficiency); risk and predictive factors; efficacy and usefulness in detection of laboratory markers, electrocardiographic changes and cardiac imaging; and specific treatment, including a novel agent, uridine triacetate." | 2.58 | Fluoropyrimidine-induced cardiotoxicity. ( Aglietta, M; Bonzano, A; Cagnazzo, C; Depetris, I; Filippi, R; Leone, F; Marino, D, 2018) |
| " TAS-102 is an oral combination therapy consisting of trifluridine (FTD), a thymidine-based nucleoside analog, plus tipiracil hydrochloride (TPI), a novel thymidine phosphorylase inhibitor that improves the bioavailability of FTD." | 2.52 | TAS-102, a novel antitumor agent: a review of the mechanism of action. ( Lenz, HJ; Loupakis, F; Stintzing, S, 2015) |
| "DPD-deficient cancer patients may be at risk of severe and sometimes lethal toxicity after the administration of 5-FU." | 2.48 | [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil]. ( Dołegowska, B; Ostapowicz, A, 2012) |
| "The main purpose of the present review article was to shed light on the different 5-fluorouracil (5-FU) prodrugs by underlining their respective pharmacological features in terms of metabolic activation, dihydropyrimidine dehydrogenase inhibition, pharmacokinetic profile and biomodulation ability." | 2.42 | Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. ( Ferrero, JM; François, E; Milano, G, 2004) |
| "Eniluracil is a promising drug, which permits reliable and safe administration of oral 5-FU and has the potential to overcome 5-FU resistance mediated by overexpression of DPD." | 2.41 | Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. ( Kindler, HL; Schilsky, RL, 2000) |
| "Eniluracil/5-FU has demonstrated efficacy as monotherapy in patients with a variety of solid tumors when given on a 5 or 28-day dosing schedule." | 2.41 | Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors. ( Hohneker, J; Levin, J, 2000) |
| "The development of anticancer drugs has conventionally focused on intravenous rather than oral regimens." | 2.41 | Novel oral chemotherapy agents. ( Hoff, PM; Pazdur, R; Royce, ME, 2000) |
| " The supply of folate depends primarily on the quantity and bioavailability of ingested folate and the rate of loss by urinary and fecal routes and through catabolism." | 2.41 | Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements. ( Gaté, L; Machover, D; Tapiero, H; Tew, KD, 2001) |
| " The unpredictable and low oral bioavailability of 5FU initially discouraged this form of treatment." | 2.41 | The oral fluorinated pyrimidines. ( de Bono, JS; Twelves, CJ, 2001) |
| "(1986) Cancer Res." | 2.40 | Mutagenic and epigenetic effects of DNA methylation. ( Gonzalgo, ML; Jones, PA, 1997) |
| "Tegafur acts as a prodrug of 5-fluorouracil (5-FU), being slowly metabolized by cytochrome P450 to 5-FU." | 2.40 | UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. ( Benner, SE; Canetta, R; Hoff, PM; Pazdur, R, 1998) |
| "Uracil was measured using an in-house LC-MS/MS method." | 1.91 | Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines. ( Greibe, E; Hoffmann-Lücke, E; Tybirk, L, 2023) |
| "These results are mainly attributed to cancer cell microenvironment-triggered release of mercury ions from disassembled nanoparticles, which rapidly induce massive levels of apoptosis in cancer cells." | 1.91 | Photoreactive Mercury-Containing Metallosupramolecular Nanoparticles with Tailorable Properties That Promote Enhanced Cellular Uptake for Effective Cancer Chemotherapy. ( Cheng, CC; Chiu, CW; Huang, CW; Huang, SY; Ilhami, FB; Lai, JY; Lee, DJ; Manayia, AH; Su, TH, 2023) |
| " Tolerance was good and 5-FU dosing was next shifted to 25% reduction, then further shifted to normal dosing at the 5th course, with still no sign for drug-related toxicities." | 1.72 | Renal impairment and DPD testing: Watch out for false-positive results! ( Carriat, L; Ciccolini, J; Quaranta, S; Rony, M; Solas, C, 2022) |
| "Multiple solid cancers distantly increase expression of Nnmt and its product 1-methylnicotinamide (MNAM) in the liver." | 1.72 | Remote solid cancers rewire hepatic nitrogen metabolism via host nicotinamide-N-methyltransferase. ( Bamba, T; Enya, S; Hamanishi, J; Harata, A; Hojo, H; Izumi, Y; Kashio, S; Kawamoto, H; Kawaoka, S; Konishi, R; Mandai, M; Miura, M; Mizuno, R; Nakao, M; Suzuki, Y; Takahashi, M; Yoda, M, 2022) |
| "The mutations found in murine tumors are similar to those found in human skin cancers, and PMA promotes proliferation of human skin cells." | 1.51 | A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils. ( Bhagwat, AS; Perera, MLW; Senevirathne, V; Siriwardena, SU; Stewart, J, 2019) |
| "Uracil was superior to the dihydrouracil/uracil ratio as a predictor of severe toxicity." | 1.46 | Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. ( Aliev, A; Beijnen, JH; Cats, A; de Boer, A; de Vries, N; Deenen, MJ; Henricks, LM; Jacobs, BAW; Mandigers, CMPW; Meulendijks, D; Rosing, H; Schellens, JHM; Soesan, M; van Werkhoven, E, 2017) |
| "Uridine is a natural nucleoside precursor of uridine monophosphate in organisms and thus is considered to be safe and is used in a wide range of clinical settings." | 1.43 | Uridine homeostatic disorder leads to DNA damage and tumorigenesis. ( Cai, C; Cao, D; Cao, Z; Chen, X; Huang, D; Ma, J; Zhang, X; Zhou, B, 2016) |
| " GNMT expression in vivo improves folate retention and bioavailability in the liver." | 1.42 | Regulation of Folate-Mediated One-Carbon Metabolism by Glycine N-Methyltransferase (GNMT) and Methylenetetrahydrofolate Reductase (MTHFR). ( Chiang, EP; Ko, HA; Lin, YJ; Tang, FY; Wang, YC; Wu, MT, 2015) |
| "5-Fluorouracil (5-FU) is a mainstay for treating various solid tumours in adults, including digestive and head and neck cancers." | 1.37 | 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases. ( Ciccolini, J; Cordier, PY; Lacarelle, B; Mercier, C; Nau, A; Oliver, M; Peytel, E, 2011) |
| "On using low TP-expressing tumors and TP blocking studies as controls, minor TP-specific accumulation of the radiotracer was detected in these studies." | 1.36 | In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging. ( Akizawa, H; Kuge, Y; Nishijima, K; Ohkura, K; Seki, K; Takahashi, M; Tamaki, N; Zhao, S, 2010) |
| "In non-small cell lung cancers, high TK-1 expression was demonstrated in squamous cell carcinomas, but not in adenocarcinomas." | 1.36 | Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer. ( Kamoshida, S; Kuroda, M; Shintani, M; Takakuwa, Y; Urano, M, 2010) |
| "S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0." | 1.36 | Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? ( Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T, 2010) |
| "In the A549 tumors, the combination produced tumor regressions." | 1.35 | Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap. ( Klein, RS; Lu, H; Schwartz, EL, 2009) |
| " Pharmacokinetic variables were determined using noncompartmental methods." | 1.33 | The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. ( Desmond, RA; Diasio, RB; Fourie, J; Hirao, Y; King, JR; Koga, T; Mattison, LK; Shimizu, T, 2006) |
| " As a single agent, S-1 showed higher antitumor activity with its low intestinal toxicity compared to continuous venous infusion 5-FU, the most effective dosing method of 5-FU, and/or to clinically available oral fluoropyrimidines such as UFT, doxyfluridine and capecitabine on various murine tumors and human tumor xenografts." | 1.33 | [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. ( Fukushima, M, 2006) |
| "Eniluracil is an inactivator of dihydropyrimidine dehydrogenase, the first enzyme in the catabolic pathway of 5-fluorouracil (5-FU)." | 1.32 | A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). ( Beale, P; Ertel, P; Judson, I; O'Donnell, A; Punt, CJ; Suttle, AB; Van Maanen, L, 2003) |
| " L(-)I-OddU is the most potent anti-Epstein-Barr Virus (EBV) compound without cytotoxicity and animal toxicity upon long-term dosing which gives the pharmacological levels of the drug in plasma." | 1.31 | Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers. ( Cheng, YC, 2001) |
| " These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5." | 1.30 | Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ( Brown, N; Covington, W; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Pazdur, R, 1998) |
| "Clinical samples of human tumors and adjacent normal tissues were assayed for phosphorolytic activity and sensitivity to 5-benzylacyclouridine (BAU), a potent inhibitor of the enzyme presently in Phase I-II clinical trial." | 1.30 | Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors. ( Cao, D; Handschumacher, RE; Liu, M; Pizzorno, G; Russell, R, 1998) |
| "FT and 5-FU fractions in cancer tissues were found to be higher than those of the patients receiving only 800 mg of Tegafur fine granules as previously reported." | 1.27 | [UFT concentration in various tissues from cancer patients]. ( Bekki, E; Hashimoto, I; Kasai, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishi, H; Nishindai, H; Sawada, Y; Yoshimoto, M, 1983) |
| " Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass." | 1.27 | [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. ( Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983) |
| " Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness." | 1.27 | [Report on nationwide pooled data and cohort investigation in UFT phase II study]. ( Kimura, K; Ota, K; Taguchi, T, 1987) |
| " Although average values of the skin reaction after dosing were slightly lower compared to those before dosing in group B, sensitization was effective." | 1.27 | [Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)]. ( Ishikawa, M; Kumazawa, H; Rei, S; Saito, H, 1987) |
| "A clinical and pharmacokinetic investigation of prolonged administration of high-dose uridine was performed in seven patients with advanced-stage cancer." | 1.27 | Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity. ( Kraal, I; Leyva, A; Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1986) |
| "Some of these solid tumors contain greater amounts of activity than do their normal equivalents, which encourages the use of inhibitors of this enzyme in conjunction with treatment of these tumors by 5-fluorouracil." | 1.27 | Enzymes of uracil catabolism in normal and neoplastic human tissues. ( Cha, S; el Kouni, MH; Naguib, FN, 1985) |
| "Fifteen cases with advanced cancer were treated with UFD-1 (mixture of FD-1 and uracil under molar ratio of 1: 20) in a daily dose of 300 mg of FD-1." | 1.26 | [Clinical experiences with UFD-1]. ( Furue, H, 1982) |
| "The metabolic incorporation by tumors of this DNA-precursor indicates a potential value of this radiocompound for their detection, differentiation and follow-up of their evolution after therapy." | 1.26 | Radioactive nucleic acids-precursors: their potential value as tumor-localizing agents. ( Anghileri, LJ; Heidbreder, M; Mathes, R, 1977) |
| " The 5-fluoro-uracil was given intravenously at a relatively nontoxic dosage level." | 1.24 | The potentiation of radiation effects with 5-fluoro-uracil. ( FOYE, LV; HALL, B; ROTH, M; WILLETT, FM, 1960) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 110 (49.33) | 18.7374 |
| 1990's | 28 (12.56) | 18.2507 |
| 2000's | 42 (18.83) | 29.6817 |
| 2010's | 30 (13.45) | 24.3611 |
| 2020's | 13 (5.83) | 2.80 |
| Authors | Studies |
|---|---|
| Mizuno, R | 1 |
| Hojo, H | 1 |
| Takahashi, M | 2 |
| Kashio, S | 1 |
| Enya, S | 1 |
| Nakao, M | 1 |
| Konishi, R | 1 |
| Yoda, M | 1 |
| Harata, A | 1 |
| Hamanishi, J | 1 |
| Kawamoto, H | 1 |
| Mandai, M | 1 |
| Suzuki, Y | 1 |
| Miura, M | 1 |
| Bamba, T | 1 |
| Izumi, Y | 1 |
| Kawaoka, S | 1 |
| Dogan, S | 1 |
| Spahiu, E | 1 |
| Cilic, A | 1 |
| Carriat, L | 1 |
| Quaranta, S | 3 |
| Solas, C | 2 |
| Rony, M | 1 |
| Ciccolini, J | 4 |
| Chen, J | 1 |
| Liao, W | 1 |
| Peng, H | 1 |
| Paulsen, NH | 1 |
| Qvortrup, C | 1 |
| Vojdeman, FJ | 1 |
| Plomgaard, P | 1 |
| Andersen, SE | 1 |
| Ramlov, A | 1 |
| Bertelsen, B | 1 |
| Rossing, M | 1 |
| Nielsen, CG | 1 |
| Hoffmann-Lücke, E | 2 |
| Greibe, E | 2 |
| Spangsberg Holm, H | 1 |
| Nielsen, HH | 1 |
| Lolas, IBY | 1 |
| Madsen, JS | 1 |
| Bergmann, ML | 1 |
| Mørk, M | 1 |
| Fruekilde, PBN | 1 |
| Bøttger, P | 1 |
| Petersen, PC | 1 |
| Nissen, PH | 1 |
| Feddersen, S | 1 |
| Bergmann, TK | 1 |
| Pfeiffer, P | 1 |
| Damkier, P | 1 |
| Tybirk, L | 1 |
| Manayia, AH | 1 |
| Ilhami, FB | 1 |
| Huang, SY | 1 |
| Su, TH | 1 |
| Huang, CW | 1 |
| Chiu, CW | 1 |
| Lee, DJ | 1 |
| Lai, JY | 1 |
| Cheng, CC | 1 |
| Alieva, NO | 1 |
| Efremov, AK | 1 |
| Hu, S | 1 |
| Oh, D | 1 |
| Chen, Z | 1 |
| Natarajan, M | 1 |
| Ong, HT | 1 |
| Jégou, A | 1 |
| Romet-Lemonne, G | 1 |
| Groves, JT | 1 |
| Sheetz, MP | 1 |
| Yan, J | 1 |
| Bershadsky, AD | 1 |
| Basbous, J | 1 |
| Aze, A | 1 |
| Chaloin, L | 1 |
| Lebdy, R | 1 |
| Hodroj, D | 1 |
| Ribeyre, C | 1 |
| Larroque, M | 1 |
| Shepard, C | 1 |
| Kim, B | 1 |
| Pruvost, A | 1 |
| Moreaux, J | 1 |
| Maiorano, D | 1 |
| Mechali, M | 1 |
| Constantinou, A | 1 |
| Dicembrini, I | 1 |
| Nreu, B | 1 |
| Montereggi, C | 1 |
| Mannucci, E | 1 |
| Monami, M | 1 |
| Marin, C | 1 |
| Krache, A | 1 |
| Palmaro, C | 1 |
| Lucas, M | 1 |
| Hilaire, V | 1 |
| Ugdonne, R | 1 |
| De Victor, B | 1 |
| Lacarelle, B | 2 |
| Puri, S | 1 |
| Juvale, K | 1 |
| Knikman, JE | 1 |
| Gelderblom, H | 2 |
| Beijnen, JH | 2 |
| Cats, A | 2 |
| Guchelaar, HJ | 2 |
| Henricks, LM | 2 |
| Meulendijks, D | 1 |
| Jacobs, BAW | 1 |
| Aliev, A | 1 |
| Deenen, MJ | 1 |
| de Vries, N | 1 |
| Rosing, H | 1 |
| van Werkhoven, E | 1 |
| de Boer, A | 1 |
| Mandigers, CMPW | 1 |
| Soesan, M | 1 |
| Schellens, JHM | 1 |
| Wang, F | 1 |
| Zahid, OK | 1 |
| Swain, BE | 1 |
| Parsonage, D | 1 |
| Hollis, T | 1 |
| Harvey, S | 1 |
| Perrino, FW | 1 |
| Kohli, RM | 1 |
| Taylor, EW | 1 |
| Hall, AR | 1 |
| Loriot, MA | 1 |
| Thomas, F | 1 |
| Barin-Le-Guellec, C | 1 |
| Royer, B | 1 |
| Milano, G | 3 |
| Picard, N | 1 |
| Becquemont, L | 1 |
| Verstuyft, C | 1 |
| Narjoz, C | 1 |
| Schmitt, A | 1 |
| Bobin-Dubigeon, C | 1 |
| Harle, A | 1 |
| Paci, A | 1 |
| Poinsignon, V | 1 |
| Evrard, A | 1 |
| Hennart, B | 1 |
| Broly, F | 1 |
| Fonrose, X | 1 |
| Lafay-Chebassier, C | 1 |
| Wozny, AS | 1 |
| Masskouri, F | 1 |
| Boyer, JC | 1 |
| Etienne-Grimaldi, MC | 1 |
| Depetris, I | 1 |
| Marino, D | 1 |
| Bonzano, A | 1 |
| Cagnazzo, C | 1 |
| Filippi, R | 1 |
| Aglietta, M | 1 |
| Leone, F | 1 |
| Siriwardena, SU | 1 |
| Perera, MLW | 1 |
| Senevirathne, V | 1 |
| Stewart, J | 1 |
| Bhagwat, AS | 1 |
| Saif, MW | 2 |
| Rosen, L | 1 |
| Rudek, MA | 1 |
| Sun, W | 4 |
| Shepard, DR | 1 |
| Becerra, C | 1 |
| Yamashita, F | 1 |
| Bebeau, P | 1 |
| Winkler, R | 1 |
| Robert, J | 1 |
| Ostapowicz, A | 1 |
| Dołegowska, B | 1 |
| Opdam, FL | 1 |
| Modak, AS | 1 |
| Weeks, LD | 1 |
| Zentner, GE | 1 |
| Scacheri, PC | 1 |
| Gerson, SL | 2 |
| Lenz, HJ | 1 |
| Stintzing, S | 1 |
| Loupakis, F | 1 |
| Wang, YC | 1 |
| Wu, MT | 1 |
| Lin, YJ | 1 |
| Tang, FY | 1 |
| Ko, HA | 1 |
| Chiang, EP | 1 |
| Uboha, N | 1 |
| Hochster, HS | 1 |
| Lee, JJ | 1 |
| Seraj, J | 2 |
| Yoshida, K | 3 |
| Mizuguchi, H | 2 |
| Strychor, S | 1 |
| Fiejdasz, J | 1 |
| Faulkner, T | 1 |
| Parise, RA | 1 |
| Fawcett, P | 1 |
| Pollice, L | 1 |
| Mason, S | 1 |
| Hague, J | 1 |
| Croft, M | 1 |
| Nugteren, J | 1 |
| Tedder, C | 1 |
| Chu, E | 1 |
| Beumer, JH | 1 |
| Cao, Z | 1 |
| Ma, J | 1 |
| Chen, X | 1 |
| Zhou, B | 1 |
| Cai, C | 1 |
| Huang, D | 1 |
| Zhang, X | 1 |
| Cao, D | 2 |
| Yoshino, T | 2 |
| Kojima, T | 2 |
| Bando, H | 1 |
| Yamazaki, T | 1 |
| Naito, Y | 1 |
| Mukai, H | 1 |
| Fuse, N | 1 |
| Goto, K | 1 |
| Ito, Y | 1 |
| Doi, T | 2 |
| Ohtsu, A | 2 |
| Bendell, JC | 1 |
| Patel, MR | 1 |
| Weaver, R | 1 |
| Lemech, C | 1 |
| Todaro, TG | 1 |
| Pant, S | 1 |
| Arkenau, HT | 1 |
| Yan, Y | 1 |
| Han, X | 1 |
| Qing, Y | 1 |
| Condie, AG | 1 |
| Gorityala, S | 1 |
| Yang, S | 1 |
| Xu, Y | 1 |
| Zhang, Y | 1 |
| Li, DZ | 1 |
| Zhang, QZ | 1 |
| Wang, CY | 1 |
| Zhang, YL | 1 |
| Li, XY | 1 |
| Huang, JT | 1 |
| Liu, HY | 1 |
| Fu, ZD | 1 |
| Song, HX | 1 |
| Lin, JP | 1 |
| Ji, TF | 1 |
| Pan, XD | 1 |
| Becerra, CR | 1 |
| Patel, M | 1 |
| Von Hoff, D | 2 |
| Overman, MJ | 2 |
| Varadhachary, G | 2 |
| Kopetz, S | 2 |
| Thomas, MB | 1 |
| Fukushima, M | 4 |
| Kuwata, K | 3 |
| Mita, A | 3 |
| Wolff, RA | 2 |
| Hoff, PM | 5 |
| Xiong, H | 2 |
| Abbruzzese, JL | 3 |
| Berger, SH | 1 |
| Pittman, DL | 1 |
| Wyatt, MD | 1 |
| Svobaite, R | 1 |
| Solassol, I | 1 |
| Pinguet, F | 1 |
| Ivanauskas, L | 1 |
| Brès, J | 1 |
| Bressolle, FM | 1 |
| Pérez-Zúñiga, FJ | 1 |
| Günther Sillero, MA | 1 |
| Sillero, A | 1 |
| Hoff, P | 1 |
| Hamada, C | 1 |
| Oliński, R | 2 |
| Jurgowiak, M | 2 |
| Lu, H | 1 |
| Klein, RS | 1 |
| Schwartz, EL | 1 |
| Ishii, Y | 1 |
| Suzuki, S | 1 |
| Takahashi, Y | 1 |
| Takayama, T | 1 |
| Asai, S | 1 |
| Shintani, M | 1 |
| Urano, M | 1 |
| Takakuwa, Y | 1 |
| Kuroda, M | 1 |
| Kamoshida, S | 1 |
| Akizawa, H | 1 |
| Zhao, S | 1 |
| Nishijima, K | 1 |
| Kuge, Y | 1 |
| Tamaki, N | 1 |
| Seki, K | 1 |
| Ohkura, K | 1 |
| Zaremba, T | 1 |
| Cordier, PY | 1 |
| Nau, A | 1 |
| Oliver, M | 1 |
| Mercier, C | 1 |
| Peytel, E | 1 |
| Shah, SK | 1 |
| Walker, PA | 1 |
| Moore-Olufemi, SD | 1 |
| Sundaresan, A | 1 |
| Kulkarni, AD | 1 |
| Andrassy, RJ | 1 |
| Schmiedt, CW | 1 |
| Saba, CF | 1 |
| Freeman, KG | 1 |
| Edwards, GL | 1 |
| Boku, N | 1 |
| Onozawa, Y | 1 |
| Fukutomi, A | 1 |
| Hironaka, S | 1 |
| Koizumi, W | 1 |
| Sasaki, T | 1 |
| Malet-Martino, M | 1 |
| Martino, R | 1 |
| Morgan-Meadows, S | 1 |
| Thomas, JP | 2 |
| Mulkerin, D | 1 |
| Berlin, JD | 1 |
| Bailey, H | 1 |
| Binger, K | 1 |
| Volkman, J | 1 |
| Alberti, D | 1 |
| Feierabend, C | 1 |
| Marrocha, R | 1 |
| Arzoomanian, RZ | 1 |
| Wilding, G | 2 |
| O'Donnell, A | 1 |
| Punt, CJ | 1 |
| Judson, I | 1 |
| Van Maanen, L | 1 |
| Suttle, AB | 1 |
| Ertel, P | 1 |
| Beale, P | 1 |
| Guo, XD | 2 |
| Harold, N | 3 |
| Schuler, B | 2 |
| Szabo, E | 1 |
| Hamilton, JM | 2 |
| Monahan, BP | 2 |
| Quinn, MG | 2 |
| Cliatt, J | 1 |
| Nguyen, D | 1 |
| Grollman, F | 2 |
| Thomas, RR | 1 |
| McQuigan, EA | 1 |
| Wilson, R | 1 |
| Takimoto, CH | 2 |
| Grem, JL | 3 |
| Peters, GJ | 2 |
| Noordhuis, P | 1 |
| Van Kuilenburg, AB | 1 |
| Schornagel, JH | 1 |
| Gall, H | 1 |
| Turner, SL | 1 |
| Swart, MS | 1 |
| Voorn, D | 1 |
| Van Gennip, AH | 1 |
| Wanders, J | 1 |
| Holwerda, U | 1 |
| Smid, K | 1 |
| Giaccone, G | 1 |
| Fumoleau, P | 1 |
| Van Groeningen, CJ | 2 |
| PRUSOFF, WH | 1 |
| HOLMES, WL | 1 |
| WELCH, AD | 2 |
| HEIDELBERGER, C | 5 |
| CHAUDHURI, NK | 1 |
| DANNEBERG, P | 1 |
| MOOREN, D | 1 |
| GRIESBACH, L | 1 |
| DUSCHINSKY, R | 1 |
| SCHNITZER, RJ | 1 |
| PLEVEN, E | 1 |
| SCHEINER, J | 1 |
| LEIBMAN, KC | 1 |
| HARBERS, E | 1 |
| BHARGAVA, PM | 1 |
| PEREVODCHIKOVA, NJ | 1 |
| REICHARD, P | 3 |
| SKOLD, O | 3 |
| CURRERI, AR | 1 |
| ANSFIELD, FJ | 1 |
| McIVER, FA | 1 |
| WAISMAN, HA | 1 |
| SORM, F | 2 |
| KEILOVA, H | 1 |
| JAFFE, JJ | 1 |
| COOPER, JR | 1 |
| VISHNIAKOVA, EG | 1 |
| KLEIN, G | 1 |
| SYRKIN, AB | 1 |
| CANTAROW, A | 4 |
| WILLIAMS, TL | 2 |
| PASCHKIS, KE | 3 |
| CORNELL, GN | 1 |
| CAHOW, CE | 1 |
| FREY, C | 1 |
| McSHERRY, C | 1 |
| BEAL, JM | 1 |
| FOYE, LV | 2 |
| WILLETT, FM | 2 |
| HALL, B | 2 |
| ROTH, M | 2 |
| FRANK, W | 3 |
| BRENNAN, JT | 2 |
| LOPRESTI, JM | 1 |
| GOLDE, A | 1 |
| VIGIER, P | 1 |
| GRIFFING, J | 1 |
| SAYLER, C | 1 |
| VANN, P | 1 |
| SENSENBRENNER, L | 1 |
| HALL, BE | 3 |
| GOOD, JW | 3 |
| HONIG, GR | 1 |
| DAVIS, JR | 1 |
| BUSCH, H | 3 |
| LIPETZ, J | 1 |
| STONIER, T | 1 |
| WEISS, AJ | 2 |
| JACKSON, L | 1 |
| WINKLER, A | 1 |
| SKODA, J | 1 |
| UJHAZY, V | 1 |
| CERNY, V | 1 |
| SANDOR, L | 1 |
| BRENNAN, MJ | 1 |
| VAITKEVICIUS, VK | 1 |
| YOUNG, CW | 1 |
| ELLISON, RR | 1 |
| SULLIVAN, RD | 2 |
| LEVICK, SN | 1 |
| KAUFMAN, R | 1 |
| MILLER, E | 2 |
| WOLDOW, I | 1 |
| ESCHER, G | 1 |
| LI, MC | 1 |
| KARNOFSKY, DA | 1 |
| BURCHENAL, JH | 1 |
| ALLAIRE, FJ | 1 |
| THIEME, ET | 1 |
| KORST, DR | 1 |
| BAINES, CJ | 1 |
| LEY, DC | 1 |
| BYVOET, P | 1 |
| RUPP, JJ | 1 |
| CHRISTIAN, GD | 1 |
| PURDY, WC | 1 |
| CREWS, QE | 1 |
| EYERLY, RC | 1 |
| NEWCOMER, KL | 2 |
| CIRKSENA, WJ | 2 |
| BAUER, AJ | 1 |
| BLOM, J | 1 |
| HAGGMARK, A | 1 |
| SCHNEIDERMAN, MA | 1 |
| CHRYSSOCHOOS, T | 1 |
| WATKINS, E | 1 |
| TARR, N | 1 |
| THURMAN, WG | 1 |
| LEUBNER, H | 1 |
| SCHUMACHER, HR | 1 |
| O'CONNELL, JP | 1 |
| WU, C | 1 |
| BAUER, JM | 1 |
| JACKSON, LG | 1 |
| CARABASI, R | 1 |
| WHITE, JE | 1 |
| RICKETTS, WN | 1 |
| STRUDWICK, WJ | 1 |
| WINSTON, JH | 1 |
| MATHIS, PL | 1 |
| EDWARDS, MD | 1 |
| HAREL, J | 1 |
| HAREL, L | 1 |
| LACOUR, F | 1 |
| BOER, A | 1 |
| IMBENOTTE, J | 1 |
| DALMAUCIRIA, M | 1 |
| AKSAMITNAIA, Ia | 1 |
| TRAPEZNIKOV, NN | 1 |
| AVDEEVA, IA | 1 |
| FRITZSON, P | 1 |
| INNES, J | 1 |
| BATEMAN, JR | 1 |
| JACOBS, EM | 1 |
| MARSH, AA | 1 |
| STEINFELD, JL | 1 |
| ZIMMERMAN, M | 1 |
| SEIDENBERG, J | 1 |
| DUBICKI, H | 1 |
| ZIELINSKI, F | 1 |
| STARKS, FW | 1 |
| CHANG, M | 1 |
| POLKINA, R | 1 |
| BYCHENKOVA, M | 1 |
| ZALESSKAYA, L | 1 |
| CAVANAGH, D | 1 |
| MARTIN, DS | 1 |
| FERGUSON, JH | 1 |
| BOOHAR, J | 1 |
| KAMPSCHROER, B | 1 |
| SATO, K | 1 |
| LEPAGE, GA | 1 |
| MORSE, PA | 1 |
| POTTER, VR | 1 |
| OKAMURA, N | 1 |
| LEMON, HM | 1 |
| LEONARDI, A | 1 |
| PALMA, V | 1 |
| OLSON, KB | 1 |
| GREENE, JR | 1 |
| JACQUEZ, JA | 1 |
| KENNEDY, BJ | 1 |
| THEOLOGIDES, A | 1 |
| KLEIN, E | 2 |
| HELM, F | 2 |
| MILGROM, H | 2 |
| STOLL, HL | 1 |
| TRAENKLE, HL | 1 |
| AMBRUS, J | 1 |
| TRAENKEL, HL | 1 |
| STOLL, HS | 1 |
| RIEBELING, M | 1 |
| ROCHLIN, DB | 1 |
| SHINER, J | 1 |
| LANGDON, E | 1 |
| OTTOMAN, R | 1 |
| STASNEY, J | 1 |
| Veronese, ML | 1 |
| Stevenson, JP | 2 |
| Redlinger, M | 2 |
| Algazy, K | 1 |
| Giantonio, B | 1 |
| Hahn, S | 1 |
| Vaughn, D | 1 |
| Thorn, C | 1 |
| Whitehead, AS | 1 |
| Haller, DG | 1 |
| O'Dwyer, PJ | 2 |
| Ferrero, JM | 1 |
| François, E | 1 |
| Hrdlicka, PJ | 1 |
| Jepsen, JS | 1 |
| Wengel, J | 1 |
| Glava-Obrovac, L | 1 |
| Karner, I | 1 |
| Pavlak, M | 1 |
| Radacić, M | 1 |
| Kasnar-Samprec, J | 1 |
| Zinić, B | 1 |
| Pérez-Pérez, MJ | 1 |
| Priego, EM | 1 |
| Hernández, AI | 1 |
| Camarasa, MJ | 1 |
| Balzarini, J | 1 |
| Liekens, S | 1 |
| Mattison, LK | 1 |
| Fourie, J | 1 |
| Hirao, Y | 1 |
| Koga, T | 1 |
| Desmond, RA | 1 |
| King, JR | 1 |
| Shimizu, T | 1 |
| Diasio, RB | 3 |
| Jiang, YL | 1 |
| Chung, S | 1 |
| Krosky, DJ | 1 |
| Stivers, JT | 1 |
| Hirata, K | 1 |
| Horikoshi, N | 1 |
| Tominaga, K | 1 |
| Sohma, K | 1 |
| Yamaguchi, K | 1 |
| Okazaki, M | 1 |
| Furuhata, T | 1 |
| Sasaki, K | 1 |
| Nakano, Y | 1 |
| Ishizuka, H | 1 |
| Yamada, Y | 1 |
| Uno, S | 1 |
| Taguchi, T | 6 |
| Yamamitsu, S | 1 |
| Shirasaka, T | 1 |
| Hong, DS | 1 |
| Bogaard, K | 1 |
| Lassere, Y | 3 |
| El-Rayes, BF | 1 |
| Zalupski, M | 2 |
| Shields, AF | 1 |
| Manza, SG | 1 |
| LoRusso, P | 1 |
| Philip, PA | 2 |
| Kimura, K | 4 |
| Suga, S | 1 |
| Kasai, Y | 1 |
| Nakanishi, Y | 1 |
| Nishi, H | 1 |
| Nishindai, H | 1 |
| Yoshimoto, M | 1 |
| Nakamura, T | 1 |
| Hashimoto, I | 1 |
| Sawada, Y | 1 |
| Mikami, J | 1 |
| Bekki, E | 1 |
| Kamiya, O | 1 |
| Hoshino, A | 1 |
| Ohara, K | 1 |
| Nagata, K | 1 |
| Sugihara, T | 1 |
| Yamada, M | 1 |
| Suzuki, M | 1 |
| Fujii, S | 1 |
| Fujita, H | 1 |
| Rochowska, M | 1 |
| Siedlecki, J | 1 |
| Skurzak, H | 1 |
| Wright, G | 1 |
| Zmudzka, B | 1 |
| Sakurai, Y | 1 |
| Tschiersch, B | 1 |
| Furue, H | 1 |
| Wasternack, C | 1 |
| Schilsky, RL | 3 |
| Janisch, L | 2 |
| Berezin, F | 1 |
| Mick, R | 1 |
| Vogelzang, NJ | 2 |
| Ratain, MJ | 3 |
| Kurihara, M | 2 |
| Eckardt, J | 1 |
| Eckhardt, G | 1 |
| Villalona-Calero, M | 1 |
| Drengler, R | 2 |
| Rowinsky, EK | 3 |
| Pazdur, R | 6 |
| Diaz-Canton, E | 1 |
| Bready, B | 1 |
| Ho, DH | 2 |
| Baker, SD | 1 |
| Khor, SP | 2 |
| Adjei, AA | 2 |
| Doucette, M | 1 |
| Spector, T | 1 |
| Donehower, RC | 1 |
| Grochow, LB | 1 |
| Sartorius, SE | 1 |
| Noe, DA | 1 |
| Hohneker, JA | 1 |
| Blount, BC | 1 |
| Mack, MM | 1 |
| Wehr, CM | 1 |
| MacGregor, JT | 1 |
| Hiatt, RA | 1 |
| Wang, G | 1 |
| Wickramasinghe, SN | 1 |
| Everson, RB | 1 |
| Ames, BN | 1 |
| Gonzalgo, ML | 1 |
| Jones, PA | 1 |
| Hohneker, J | 2 |
| Smetzer, L | 1 |
| Lucas, VS | 1 |
| Diasio, R | 1 |
| Von Hoff, DD | 1 |
| Burris, HA | 1 |
| Sumi, S | 1 |
| Kidouchi, K | 1 |
| Hayashi, K | 1 |
| Imaeda, M | 1 |
| Asai, M | 1 |
| Wada, Y | 1 |
| Covington, W | 1 |
| Brown, N | 1 |
| Huo, YY | 1 |
| Kuritani, J | 1 |
| Liu, M | 1 |
| Russell, R | 1 |
| Handschumacher, RE | 1 |
| Pizzorno, G | 1 |
| Benner, SE | 1 |
| Canetta, R | 1 |
| DeMario, MD | 1 |
| Mani, S | 1 |
| Vokes, EE | 1 |
| Fleming, GF | 1 |
| Melton, K | 1 |
| Johnson, S | 1 |
| Benner, S | 1 |
| Lebwohl, D | 1 |
| González Barón, M | 1 |
| Bokemeyer, C | 2 |
| Hartmann, JT | 2 |
| Kollmannsberger, C | 1 |
| Mayer, F | 2 |
| Kanz, L | 2 |
| Ibrahim, D | 1 |
| Arlauskas, P | 1 |
| Shields, A | 1 |
| Blanke, CD | 1 |
| Teng, M | 1 |
| Choy, H | 1 |
| Muto, Y | 1 |
| Takebuchi, K | 1 |
| Watanabe, M | 1 |
| Hasegawa, K | 1 |
| Sakonji, M | 1 |
| Matsukawa, M | 1 |
| Focher, F | 1 |
| Ubiali, D | 1 |
| Pregnolato, M | 1 |
| Zhi, C | 1 |
| Gambino, J | 1 |
| Wright, GE | 1 |
| Spadari, S | 1 |
| Kindler, HL | 1 |
| Levin, J | 1 |
| Böhlke, I | 1 |
| Von Pawel, J | 1 |
| Derigs, G | 1 |
| Schröder, M | 1 |
| Gojo, I | 1 |
| Tkaczuk, KH | 1 |
| Haller, D | 1 |
| Shapiro, J | 2 |
| Bi, DQ | 1 |
| Zentko, S | 2 |
| Keith, B | 2 |
| Donavan, S | 1 |
| Morrison, G | 1 |
| Ochoa, L | 1 |
| Hurwitz, HI | 1 |
| Cohen, D | 1 |
| Schwartz, G | 1 |
| Monroe, P | 1 |
| Petros, WP | 1 |
| Ertel, VP | 1 |
| Hsieh, A | 1 |
| Hoffman, C | 1 |
| Magnum, S | 1 |
| Lewis, NL | 1 |
| Meropol, NJ | 1 |
| Royce, ME | 1 |
| Wada, H | 1 |
| Cheng, YC | 1 |
| Minsky, BD | 1 |
| de Bono, JS | 1 |
| Twelves, CJ | 1 |
| Kubota, T | 1 |
| Tapiero, H | 1 |
| Tew, KD | 1 |
| Gaté, L | 1 |
| Machover, D | 1 |
| Reid, JM | 1 |
| Sloan, JA | 1 |
| Smith, DA | 1 |
| Rubin, J | 1 |
| Pitot, HC | 1 |
| Alberts, SR | 1 |
| Goldberg, RM | 1 |
| Hanson, LJ | 1 |
| Atherton, P | 1 |
| Ames, MM | 1 |
| Erlichman, C | 1 |
| Quinn, M | 1 |
| Anghileri, LJ | 1 |
| Heidbreder, M | 1 |
| Mathes, R | 1 |
| Pauly, JL | 1 |
| Schuller, MG | 1 |
| Zelcer, AA | 1 |
| Kirss, TA | 1 |
| Gore, SS | 1 |
| Germain, MJ | 1 |
| Takahashi, H | 1 |
| Kamano, T | 1 |
| Cha, SM | 1 |
| Ota, K | 2 |
| Kumazawa, H | 1 |
| Ishikawa, M | 1 |
| Rei, S | 1 |
| Saito, H | 1 |
| Yamamoto, Y | 1 |
| Amano, T | 1 |
| Imada, T | 1 |
| Tamura, S | 1 |
| Abe, M | 1 |
| Matsumoto, A | 1 |
| Leyva, A | 1 |
| Kraal, I | 1 |
| Pinedo, HM | 1 |
| Ishida, N | 1 |
| Naguib, FN | 1 |
| el Kouni, MH | 1 |
| Cha, S | 1 |
| Mishra, PC | 1 |
| Klecker, RW | 1 |
| Jenkins, JF | 1 |
| Kinsella, TJ | 1 |
| Fine, RL | 1 |
| Strong, JM | 1 |
| Collins, JM | 1 |
| Shapot, VS | 1 |
| Vornovitskaya, GI | 1 |
| Gorozhanskaya, EG | 1 |
| Davidova, SY | 1 |
| Zhubanova, AA | 1 |
| Krechetova, GD | 1 |
| Chudinova, IA | 1 |
| Hagen, U | 1 |
| Fidler, IJ | 1 |
| Lieber, S | 1 |
| Cohen, SS | 1 |
| Tanneberger, S | 1 |
| Bacigalupo, G | 1 |
| Kholodnyi, MD | 1 |
| Mindlin, SS | 1 |
| Lee, TC | 1 |
| Stöhrer, G | 1 |
| Teller, MN | 1 |
| Myles, A | 1 |
| Brown, GB | 1 |
| Rogers, WI | 1 |
| Wilson, JA | 1 |
| Smahelová, R | 1 |
| Smahel, O | 2 |
| Schück, O | 1 |
| König, J | 1 |
| Grafnetterová, J | 1 |
| Malý, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Improving the Safety of Fluoropyrimidine-based Chemotherapy by Combined DPYD Genotype-guided and DPD Phenotype-guided Dose Individualization: The ALPE2U Study[NCT04194957] | 1,440 participants (Anticipated) | Interventional | 2020-01-15 | Recruiting | |||
| A Phase 1 Study to Evaluate the Cardiac Safety of Orally Administered TAS-102 in Patients With Advanced Solid Tumors[NCT01867879] | Phase 1 | 44 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| Phase I Study of Gemcitabine (Gemzar) and UFT/Leucovorin[NCT00003925] | Phase 1 | 36 participants (Anticipated) | Interventional | 1998-05-31 | Completed | ||
| Impact of Folates in the Care of the Male Infertility[NCT01407432] | Phase 3 | 162 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
48 reviews available for uracil and Benign Neoplasms
| Article | Year |
|---|---|
Topics: Antigens, Viral, Tumor; CD8-Positive T-Lymphocytes; Humans; Immunologic Deficiency Syndromes; Immuno | 2022 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Incid | 2020 |
Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Monocarboxylic Acid Transporters; Muscle P | 2020 |
Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2021 |
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2018 |
Fluoropyrimidine-induced cardiotoxicity.
Topics: Acetates; Capecitabine; Cardiotoxicity; Cardiovascular Diseases; Drug Combinations; Fluorouracil; Hu | 2018 |
[Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Topics: Antineoplastic Agents; Biomarkers; Breath Tests; Capecitabine; Comorbidity; Deoxycytidine; Dihydropy | 2012 |
Breath tests to phenotype drug disposition in oncology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Agents; Breath Tests; Cytochrome P-450 Enzym | 2013 |
TAS-102, a novel antitumor agent: a review of the mechanism of action.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations | 2015 |
TAS-102: a novel antimetabolite for the 21st century.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2016 |
Uracil in DNA: consequences for carcinogenesis and chemotherapy.
Topics: Animals; Antineoplastic Agents; DNA; DNA Damage; Folic Acid Deficiency; Humans; Neoplasms; Uracil | 2008 |
The role of meta-analysis in cancer clinical trials.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Humans; Meta-Analysis as Topic; Neoplasms; Rectal Neopl | 2009 |
[Uracil in DNA--friend or foe?].
Topics: Animals; Cytidine Deaminase; Deoxyuracil Nucleotides; DNA; DNA Replication; Humans; Neoplasms; Retro | 2009 |
Uracil in DNA--its biological significance.
Topics: Animals; B-Lymphocytes; Cytosine; Cytosine Deaminase; DNA; Drosophila melanogaster; Escherichia coli | 2010 |
An evidence-based review of a Lentinula edodes mushroom extract as complementary therapy in the surgical oncology patient.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2004 |
Thymidine phosphorylase inhibitors: recent developments and potential therapeutic applications.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Binding Sites; Drug Design; Endothelial Growth | 2005 |
[Pharmacokinetics of S-1].
Topics: Administration, Oral; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2006 |
Studies of analogs of fluorinated pyrimidine in Japan.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluorouraci | 1981 |
[Metabolic modulation as a method in tumor chemotherapy].
Topics: Antineoplastic Agents; Cytarabine; Fluorouracil; Humans; Methotrexate; Neoplasms; Tegafur; Thymidine | 1982 |
Degradation of pyrimidines and pyrimidine analogs--pathways and mutual influences.
Topics: Aminoisobutyric Acids; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Aza Compounds; Bar | 1980 |
Clinical experience with UFT in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Japan; Neoplasms; | 1993 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1995 |
The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Mutagenic and epigenetic effects of DNA methylation.
Topics: 5-Methylcytosine; Animals; Cytosine; DNA Methylation; Enzymes; Gene Expression Regulation, Neoplasti | 1997 |
Modulation of 5-FU and its related compounds.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; | 1997 |
Experience with UFT in Japan.
Topics: Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug | 1997 |
UFT: biochemical modulation for 5-fluorouracil (5-FU).
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as | 1997 |
UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal | 1998 |
[Oral fluoropyrimidines in oncology].
Topics: Administration, Oral; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplas | 1998 |
Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Availabi | 1999 |
The University of Texas M. D. Anderson Cancer Center Orzel/UFT Investigators' Workshop and Consensus Conference. October 15-18, 1998. Proceedings.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasms; Tegafur; Uracil | 1999 |
The role of UFT in combined-modality therapy.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NAD | 2000 |
The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as | 2000 |
Clinical development of eniluracil/fluorouracil: an oral treatment for patients with solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2000 |
Oral fluoropyrimidines in cancer treatment.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo | 2000 |
Novel oral chemotherapy agents.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 2000 |
UFT plus oral leucovorin calcium (Orzel) and radiation in combined modality therapy: a comprehensive review.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinic | 2001 |
The oral fluorinated pyrimidines.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Biotransfor | 2001 |
[5-fluorouracil and dihydropyrimidine dehydrogenase].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehyd | 2001 |
Prevention of pathologies associated with oxidative stress and dietary intake deficiencies: folate deficiency and requirements.
Topics: Animals; Diet; DNA; Folic Acid; Folic Acid Deficiency; Homocysteine; Humans; Lipid Peroxidation; Neo | 2001 |
Development of inhibitors of pyrimidine metabolism.
Topics: Humans; Neoplasms; Pentosyltransferases; Pyrimidines; Structure-Activity Relationship; Thymidine Pho | 1989 |
[Isolation of factors responsible for the immunosuppression found in tumor-bearing animals].
Topics: Adenosine; Animals; Glycoproteins; Humans; Immune Tolerance; Macrophage Activation; Macrophages; Mic | 1985 |
Notes on some peculiarities of enzymic processes in malignant tumours and tissues of the host.
Topics: Adenine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Catalase; Cholesterol; DNA, Neoplasm; | 1972 |
Chemical carcinogenesis, chemotherapy: cancer's continuing core challenges--G. H. A. Clowes Memorial Lecture.
Topics: Animals; Antineoplastic Agents; Arginase; Benz(a)Anthracenes; Benzopyrenes; Carcinogens; Cell Divisi | 1970 |
32 trials available for uracil and Benign Neoplasms
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bilirubin; Drug Administration Schedule; D | 2019 |
Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.
Topics: Aged; Antineoplastic Agents; Chromatography, Liquid; Drug Combinations; Female; Humans; Male; Middle | 2016 |
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross- | 2016 |
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Drug Administr | 2016 |
A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Cross-Over Studies; Drug | 2017 |
Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Sch | 2008 |
Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neopl | 2008 |
Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Do | 2012 |
Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review.
Topics: Administration, Oral; Antineoplastic Agents; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neop | 2002 |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorou | 2002 |
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Enzyme Inhibit | 2003 |
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Dose-Respon | 2003 |
Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dos | 2004 |
Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Asthenia; Dose-Response | 2006 |
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fem | 2007 |
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Female; Humans; | 1993 |
Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Fem | 1996 |
Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase.
Topics: Absorption; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biolo | 1996 |
Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Ph | 1997 |
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dihydrouracil Dehydro | 1998 |
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1999 |
UFT/calcium folinate plus weekly paclitaxel for solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 1999 |
Gemcitabine and UFT plus oral calcium folinate: phase I study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 1999 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Re | 2000 |
A phase I study of paclitaxel, UFT, and leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Rel | 2000 |
Irinotecan and UFT/leucovorin in patients with advanced cancers.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy | 2000 |
Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2000 |
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studie | 2000 |
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2002 |
Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2002 |
[Clinical results of UFT enteric-coated granule therapy under cooperative study (phase II study). Tokyo Cancer Chemotherapy Cooperative Study Group].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 1990 |
145 other studies available for uracil and Benign Neoplasms
| Article | Year |
|---|---|
Remote solid cancers rewire hepatic nitrogen metabolism via host nicotinamide-N-methyltransferase.
Topics: Animals; Liver; Mice; Neoplasms; Niacinamide; Nicotinamide N-Methyltransferase; Nitrogen; Uracil; Ur | 2022 |
Structural Analysis of microRNAs in Myeloid Cancer Reveals Consensus Motifs.
Topics: Adenine; Base Sequence; MicroRNAs; Neoplasms; Nucleotides; Uracil | 2022 |
Renal impairment and DPD testing: Watch out for false-positive results!
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrour | 2022 |
Dihydropyrimidine dehydrogenase (DPD) genotype and phenotype among Danish cancer patients: prevalence and correlation between
Topics: Denmark; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Neoplasms; Phenotype; P | 2022 |
Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines.
Topics: Blood Specimen Collection; Chromatography, Liquid; Humans; Immunologic Factors; Neoplasms; Tandem Ma | 2023 |
Photoreactive Mercury-Containing Metallosupramolecular Nanoparticles with Tailorable Properties That Promote Enhanced Cellular Uptake for Effective Cancer Chemotherapy.
Topics: Drug Carriers; Hydrogen-Ion Concentration; Mercury; Nanoparticles; Neoplasms; Polymers; Uracil | 2023 |
Myosin IIA and formin dependent mechanosensitivity of filopodia adhesion.
Topics: Actin Cytoskeleton; Animals; Chlorocebus aethiops; COS Cells; Formins; Gene Expression Regulation, N | 2019 |
Dihydropyrimidinase protects from DNA replication stress caused by cytotoxic metabolites.
Topics: Amidohydrolases; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA Replication; H | 2020 |
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Chromatog | 2020 |
Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; | 2017 |
Solid-State Nanopore Analysis of Diverse DNA Base Modifications Using a Modular Enzymatic Labeling Process.
Topics: Adenine; Base Pair Mismatch; Biosensing Techniques; DNA; DNA Damage; DNA Repair; Epigenesis, Genetic | 2017 |
A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils.
Topics: Carcinogens; Cell Line; Cell Transformation, Neoplastic; Cytidine Deaminase; Cytosine; DNA, Single-S | 2019 |
[5-FU: At last!]
Topics: Acetates; Antidotes; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Fl | 2019 |
Fluoropyrimidines and DPD testing: is there truly an inexorable link?
Topics: Antineoplastic Agents; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP | 2019 |
Uracil DNA glycosylase (UNG) loss enhances DNA double strand break formation in human cancer cells exposed to pemetrexed.
Topics: Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; Glutamates; Guanine; Humans; | 2014 |
Regulation of Folate-Mediated One-Carbon Metabolism by Glycine N-Methyltransferase (GNMT) and Methylenetetrahydrofolate Reductase (MTHFR).
Topics: Animals; Carbon; DNA Damage; DNA Methylation; Folic Acid; Genotype; Glycine N-Methyltransferase; Hep | 2015 |
Uridine homeostatic disorder leads to DNA damage and tumorigenesis.
Topics: Animals; Cell Transformation, Neoplastic; DNA Damage; Dose-Response Relationship, Drug; Genotype; Ho | 2016 |
Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; DNA Damage; DNA Replicat | 2016 |
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoiso | 2017 |
HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Hydroxylation; Mass Spectrometry; Molecul | 2008 |
Bisphosphonates activate the 5-fluorouracil/uracil phosphoribosyltransferase activity present in Saccharomyces cerevisiae cell extracts: implications for tumor treatments.
Topics: Antimetabolites, Antineoplastic; Bone Density Conservation Agents; Diphosphonates; Fluorouracil; Neo | 2008 |
Antiangiogenic and antitumor activity of 6-(2-aminoethyl)amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protoco | 2009 |
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon H | 2010 |
Immunohistochemical characterization of pyrimidine synthetic enzymes, thymidine kinase-1 and thymidylate synthase, in various types of cancer.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Drug Resistance, Neoplasm; Humans; Immunohistoch | 2010 |
In vitro and in vivo evaluations of a radioiodinated thymidine phosphorylase inhibitor as a tumor diagnostic agent for angiogenic enzyme imaging.
Topics: Animals; Biological Transport; Cell Line, Tumor; Enzyme Inhibitors; Female; Gene Expression Regulati | 2010 |
5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Dihydropyrimidine Dehydrogenase Deficiency; Electroenc | 2011 |
Assessment of plasma uracil-to-dihydrouracil concentration ratio as an indicator of dihydropyrimidine dehydrogenase activity in clinically normal dogs and dogs with neoplasia or renal insufficiency.
Topics: Animals; Chromatography, High Pressure Liquid; Dihydrouracil Dehydrogenase (NADP); Dog Diseases; Dog | 2012 |
A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Therapy, Combination; Enzym | 2003 |
Non-utilization of radioactive iodinated uracil, uridine, and orotic acid by animal tissues in vivo.
Topics: Neoplasms; Orotic Acid; Uracil; Uridine | 1953 |
Fluorinated pyrimidines, a new class of tumour-inhibitory compounds.
Topics: Halogenation; Neoplasms; Orotic Acid; Pyrimidines; Uracil | 1957 |
The comparative utilization of uracil-2-C14 by liver, intestinal mucosa, and Flexner-Jobling carcinoma in the rat.
Topics: Animals; Carcinoma; Intestinal Mucosa; Liver; Neoplasms; Rats; Uracil | 1957 |
[Experiences with clinical use of some new chemotherapeutics in tumor therapy].
Topics: Humans; Mechlorethamine; Neoplasms; Nitrogen Mustard Compounds; Uracil | 1958 |
Enzymes of uracil metabolism in the Ehrlich ascites tumour and mammalian liver.
Topics: Animals; Biochemical Phenomena; Carcinoma, Ehrlich Tumor; Liver; Neoplasms; Uracil | 1958 |
Clinical studies with 5-fluorouracil.
Topics: Biomedical Research; Fluorouracil; Neoplasms; Uracil | 1958 |
The anti-tumour activity of 6-azauracil riboside.
Topics: Antineoplastic Agents; Humans; Neoplasms; Nucleosides; Nucleotides; Uracil | 1958 |
Enzymic ribosidation and ribotidation of 5-fluorouracil by extracts of the Ehrlich-ascites tumor.
Topics: Antineoplastic Agents; Ascites; Fluorouracil; Neoplasms; Uracil | 1958 |
Studies on 6-uracil methyl sulfone. II. Anti-tumor activity.
Topics: Antineoplastic Agents; Dimethyl Sulfoxide; Humans; Neoplasms; Sulfones; Uracil | 1958 |
[First results of dopane therapy of chronic myeloid leukemia and of certain malignant tumors].
Topics: Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mechlorethami | 1958 |
Possible enzymic mechanism for the development of resistance against fluorouracil in ascites tumours.
Topics: Antineoplastic Agents; Ascites; Biochemical Phenomena; Fluorouracil; Neoplasms; Uracil | 1959 |
[Studies on the effect of mercamine on anti-tumor activity of dopane].
Topics: Cysteamine; Mechlorethamine; Mercaptoethylamines; Neoplasms; Nitrogen Mustard Compounds; Uracil | 1959 |
Uracil incorporation in liver RNA of young and pregnant rats and in RNA of fetal tissues and certain tumors.
Topics: Animals; Female; Fetus; Liver; Neoplasms; Pregnancy; Rats; RNA; Uracil | 1961 |
Clinical experience with 5-fluorouracil (NSC-19893) in the treatment of malignant disease.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
The potentiation of radiation effects with 5-fluoro-uracil.
Topics: Aged; Carcinoma, Squamous Cell; Esophagitis; Fluorouracil; Humans; Lung; Lung Neoplasms; Male; Middl | 1960 |
Preliminary pharmacologic observations on the concomitant use of x-ray and 5-fluorouracil in human malignancies.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1961 |
[Inhibition of the development of the Rous sarcoma virus by 5-fluorouracil in tissue culture].
Topics: Fluorouracil; Neoplasms; Research Design; Rous sarcoma virus; Uracil; Viruses | 1961 |
One year's clinical experience with 5-fluorouracil and x-ray-a preliminary report.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1961 |
Treatment of advanced neoplastic disease with 5-fluorouracil and irradiation.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
Suppression of uptake of L-arginine-U-14C into chromatographically separated cationic nuclear proteins of tissues of tumour-bearing rats by 5-bis (2-chloroethyl) aminouracil.
Topics: Animals; Arginine; Biochemical Phenomena; Cations; Neoplasms; Nuclear Proteins; Nucleoproteins; Rats | 1961 |
Effect of 5-bromuracil on crown gall tumour induction.
Topics: Agrobacterium; Bromouracil; Infections; Neoplasms; Plant Tumors; Plants; Rhizobium; Uracil | 1961 |
The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
Topics: Biliary Tract; Biliary Tract Neoplasms; Digestive System Neoplasms; Fluorouracil; Gastrointestinal T | 1961 |
Excretion of 6-azauracil riboside in cancer patients.
Topics: Biochemical Phenomena; Biological Transport; Neoplasms; Nucleosides; Nucleotides; Uracil | 1960 |
5-Fluorouracil in clinical cancer experience with 155 patients.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1960 |
The potentiation of radiation effects with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1960 |
The clinical evaluation of 5-fluorouracil and 5-fluoro-2'-deoxyuridine in solid tumors in adults: a progress report.
Topics: Antineoplastic Agents; Deoxyuridine; Fluorouracil; Neoplasms; Nucleosides; Nucleotides; Research Rep | 1960 |
Cancer chemotherapy with 5-fluorouracil alone and in combination with x-ray therapy.
Topics: Fluorouracil; Humans; Neoplasms; Uracil; X-Ray Therapy | 1961 |
A preliminary report on the use of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1962 |
Intracellular distribution of 5-bis(2-chloroethyl) aminouracil-2-C-14 in tissues of tumor-bearing rats.
Topics: Animals; Antineoplastic Agents; Cytoplasm; Neoplasms; Rats; Uracil | 1962 |
Effects of 5-fluorouracil on the adrenals of normal and tumor-bearing rats.
Topics: Adrenal Glands; Animals; Cortisone; Fluorouracil; Neomycin; Neoplasms; Rats; Uracil | 1962 |
A polarographic study of copper complexes with some cancer chemotherapeutic agents.
Topics: Antineoplastic Agents; Chemistry Techniques, Analytical; Copper; Mechlorethamine; Mercaptopurine; Ne | 1961 |
Observations on the combined use of 5-fluorouracil and 2 Mev radiation in advanced solid tumors in man.
Topics: Antineoplastic Agents; Fluorouracil; Neomycin; Neoplasms; Radiation; Research; Uracil | 1961 |
The effects of 5-fluorouracil in patients with incurable cancer.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Observations on the concomitant use of x-rays and 5-fluorouracil in human malignant neoplasms.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1962 |
Further observations on the concomitant use of x rays and 5-fluorouracil in neoplasms of humans.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil; X-Rays | 1962 |
Studies on resistance against 5-fluorouracil. II. Thymidylate synthetase from drug-resistant tumor lines.
Topics: Enzymes; Fluorouracil; Humans; Neoplasms; Thymidylate Synthase; Uracil | 1962 |
Advanced neoplastic disease. Treatment with 5-fluorouracil and irradiation.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
Treatment of far-advanced cancer with 5-fluorouracil, used alone and in combination with irradiation. Incidence and duration of remission and survival-time data in 223 patients.
Topics: Antineoplastic Agents; Fluorouracil; Incidence; Neoplasms; Uracil | 1962 |
The clinical excursion into 5-fluoro-uracil.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
The clinical effects of the continuous intravenous and intra-arterial infusion of cancer chemotherapeutic compounds.
Topics: Administration, Intravenous; Antineoplastic Agents; Folic Acid Antagonists; Infusions, Intra-Arteria | 1962 |
Intra-arterial infusion of tumors with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Infusions, Intra-Arterial; Infusions, Parenteral; Neoplasms; Ur | 1962 |
Clinical screening of new agents in children with malignant disease.
Topics: Antineoplastic Agents; Neoplasms; Uracil | 1962 |
[On nucleic acids].
Topics: DNA; Fluorouracil; Metabolism; Neoplasms; Nucleic Acids; Proteins; Purines; Pyrimidines; Radiation E | 1963 |
The intravenous use of uracil mustard (U-8344). A preliminary report.
Topics: Antineoplastic Agents; Injections, Intravenous; Neoplasms; Uracil; Uracil Mustard | 1963 |
Catabolism of xanthine and uracil in tumor-bearing rats.
Topics: Animals; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Hydantoins; Liver Neoplasms; Neoplasms; N | 1962 |
An evaluation of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
A clinical study of 5-fluorouracil in a variety of far advanced human malignancies.
Topics: Antineoplastic Agents; Biomedical Research; Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Some observations of the effects of 5-fluorouracil in the treatment of malignant tumors.
Topics: Fluorouracil; Humans; Neoplasms; Uracil | 1962 |
Hormonal and nutritional influences on the incorporation of uracil into liver and tumor RNA in the rat.
Topics: Animals; Cortisone; Growth Hormone; Hypophysectomy; Liver; Neoplasms; Rats; RNA; RNA, Neoplasm; Star | 1962 |
FRACTIONS WITH DIFFERING BASE COMPOSITION IN RNA FROM MALIGNANT CELLS OF MOUSE.
Topics: Adenine; Animals; Autoradiography; Base Composition; Cytosine; Electrophoresis; Guanine; Mice; Neopl | 1963 |
[NEW ANTIBLASTIC AGENTS].
Topics: Antineoplastic Agents; Colonic Neoplasms; Ethoglucid; Fluorouracil; Neoplasm Metastasis; Neoplasms; | 1963 |
[EFFECT OF SOME PYRIMIDINE DERIVATIVES ON THE GROWTH OF CROCKER'S SARCOMA].
Topics: Animals; Antineoplastic Agents; Cytosine; Mice; Neoplasms; Pharmacology; Pyrimidines; Research; Sarc | 1963 |
PRELIMINARY DATA ON REGIONAL CHEMOTHERAPY OF MALIGNANT TUMOURS OF THE EXTREMITIES BY PERFUSION.
Topics: Adolescent; Bone Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Child; Chondrosarcoma; Dogs; F | 1964 |
[ENZYMATIC STUDIES OF CANCER].
Topics: Carcinoma, Hepatocellular; Fluorenes; Liver; Liver Neoplasms; Metabolism; Neoplasms; Neoplasms, Expe | 1964 |
ANTI-LEUKAEMIC DRUGS.
Topics: Busulfan; Chlorambucil; Cyclophosphamide; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; M | 1964 |
5-DIAZOURACIL (NSC-23519): A PHASE I STUDY.
Topics: Antimetabolites; Neoplasms; Pyrimidines; Toxicology; Uracil | 1964 |
DEOXYRIBOSYL TRANSFER. I. THYMIDINE PHOSPHORYLASE AND NUCLEOSIDE DEOXYRIBOSYLTRANSFERASE IN NORMAL AND MALIGNANT TISSUES.
Topics: Animals; Breast Neoplasms; Carcinoma; Carcinoma, Ehrlich Tumor; Cattle; Colonic Neoplasms; Cricetina | 1964 |
SYNTHESIS OF 5((2-FLUOROETHYL)(2-CHLOROETHYL)AMINO)-6-METHYLURACIL (FLUORODOPAN).
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Neoplasms; Neoplasms, Experimental; Nitrogen Musta | 1964 |
[EXPERIMENTAL STUDIES ON CARCINOMA AND ITS ARRESTED STATE. 9. PHARMACOLOGY OF URACIL MUSTARD, A CHEMOTHERAPEUTIC ANTINEOPLASTIC AGENT].
Topics: Antineoplastic Agents; Neoplasms; Neoplasms, Experimental; Nitrogen Mustard Compounds; Pharmacology; | 1964 |
RADIOSENSITIZATION OF TUMORS WITH PYRIMIDINE DERIVATIVES.
Topics: Animals; Carcinoma, Ehrlich Tumor; Melanoma; Mice; Neoplasm Transplantation; Neoplasms; Neoplasms, E | 1964 |
CLOSED PELVIC PERFUSION IN ADVANCED GYNECOLOGIC CANCER.
Topics: Catheterization; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluorouracil; F | 1965 |
FLUORINATED PYRIMIDINES. XXIV. IN VIVO METABOLISM OF 5-TRIFLUOROMETHYLURACIL-2-C-14 AND 5-TRIFLUOROMETHYL-2'-DEOXYURIDINE-2-C-14.
Topics: Animals; Carbon Isotopes; Deoxyuridine; DNA; Fluorine; Metabolism; Mice; Neoplasms; Neoplasms, Exper | 1965 |
METABOLIC EFFECTS OF AN ANTIBIOTIC, NSC-51954, ON SUSCEPTIBLE AND RESISTANT TUMOR CELLS.
Topics: Adenine; Animals; Anti-Bacterial Agents; Carbon Isotopes; Carcinoma, Ehrlich Tumor; DNA; DNA, Neopla | 1965 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
[SOME MECHANISMS AND PROBLEMS OF SELECTIVE CHEMOTHERAPY].
Topics: Antineoplastic Agents; Drug Therapy; Humans; Methotrexate; Neoplasms; Nucleosides; Uracil; Uridine | 1965 |
BASE COMPOSITION OF HIGH MOLECULAR WEIGHT NUCLEAR RNA OF WALKER TUMOR AND LIVER OF THE RAT.
Topics: Adenine; Adenine Nucleotides; Animals; Base Composition; Carcinoma 256, Walker; Cytosine; Cytosine N | 1965 |
Reduction of 5-fluorouracil toxicity in man with retention of anticancer effects by prolonged intravenous administration in 5 per cent dextrose.
Topics: Administration, Intravenous; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Glucose; | 1960 |
[Activity of fluorinated pyrimidines on the growth of human tumor cells cultured in vitro].
Topics: Biological Phenomena; Halogenation; In Vitro Techniques; Neoplasms; Nucleosides; Nucleotides; Orotic | 1959 |
Evaluation of 5-fluorouracil in the treatment of cancer.
Topics: Fluorouracil; Neoplasms; Uracil | 1960 |
Permeability of Ehrlich cells to uracil, thymine and fluorouracil.
Topics: Fluorouracil; Humans; Neoplasms; Permeability; Thymine; Uracil | 1962 |
The role of 5-fluorouracil in malignant disease.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1961 |
Tumors of the skin. II. Keratoacanthoma; local effct of 5-fluorouracil.
Topics: Fluorouracil; Humans; Keratoacanthoma; Neoplasms; Skin; Skin Neoplasms; Uracil | 1962 |
Tumors of the skin: effects of local use of cytostatic agents.
Topics: Adenocarcinoma; Cytostatic Agents; Humans; Neoplasms; Skin; Uracil | 1962 |
Biochemical changes during treatment with 5-fluorouracil.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Phosphotransferases; Uracil | 1962 |
Massive intra-aortic injections of nitrogen mustard (Dichloren), 5-fluorouracil, nitromin, and endoxan prior to roentgen irradiation for advanced tumors of the uterus.
Topics: Antineoplastic Agents; Cyclophosphamide; Female; Fluorouracil; Humans; Mechlorethamine; Neoplasms; N | 1962 |
Use of 5-fluorouracil in disseminated solid neoplasms.
Topics: Antineoplastic Agents; Fluorouracil; Neoplasms; Uracil | 1962 |
Competitive action of 2-thiouracil and uracil in AAF-induced cancer of the liver.
Topics: Carcinogenesis; Humans; Liver Neoplasms; Neoplasms; Thiouracil; Uracil | 1951 |
Synthesis and biological evaluation of conformationally restricted and nucleobase-modified analogs of the anticancer compound 3'-C-ethynylcytidine (ECyd).
Topics: Antimetabolites; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Cytidine; Drug | 2005 |
Synthesis and antitumor activity of 5-bromo-1-mesyluracil.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; DNA; Female; HeLa Cells; Humans; In Vitro Techni | 2005 |
The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Topics: Administration, Oral; Adult; Aged; Breath Tests; Carbon Dioxide; Carbon Isotopes; Chromatography, Hi | 2006 |
Synthesis and high-throughput evaluation of triskelion uracil libraries for inhibition of human dUTPase and UNG2.
Topics: Aldehydes; Binding Sites; Chromosomes, Human; Deoxyuridine; DNA; DNA Glycosylases; DNA Replication; | 2006 |
[Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2006 |
[Pharmacological and pharmacodynamic aspects of cancer chemotherapy, with special reference to 5-fluorouracil and its derivatives].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Floxuridine; Fluorouracil; Humans | 1982 |
[UFT concentration in various tissues from cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1983 |
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Pr | 1983 |
[UFT].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combina | 1984 |
[Pharmacokinetics of fluoropyrimidines].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ehrlich Tumor; Fluorouracil; Hum | 1984 |
Inhibition of calf thymus DNA polymerase alpha and of normal and cancer cell growth by butylanilinouracil and butylphenylguanine.
Topics: Animals; Cattle; Cell Division; Cell Line; DNA Polymerase I; DNA Polymerase II; DNA Polymerase III; | 1982 |
[Clinical experiences with UFD-1].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combination | 1982 |
Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage.
Topics: Chromosome Aberrations; DNA; DNA Damage; Folic Acid Deficiency; Humans; Micronucleus Tests; Neoplasm | 1997 |
UFT: East meets West in drug development.
Topics: Administration, Oral; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; | 1997 |
Urinary screening for pyrimidine metabolism disorders. Reference ranges for dihydrouracil, uracil, and dihydrouracil/uracil ratio.
Topics: Adult; Cerebral Infarction; Dihydrouracil Dehydrogenase (NADP); Female; Humans; Hypertension; Liver | 1998 |
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined | 1998 |
Expression, characterization, and detection of human uridine phosphorylase and identification of variant uridine phosphorolytic activity in selected human tumors.
Topics: Amino Acid Sequence; Animals; Antibody Specificity; Cloning, Molecular; DNA, Complementary; Drug Scr | 1998 |
[Consideration of cancer home chemotherapy with cooperation between hospital and clinic].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cooperative Behavior; Drug Administration | 1999 |
Novel nonsubstrate inhibitors of human thymidine phosphorylase, a potential target for tumor-dependent angiogenesis.
Topics: Amino Acid Sequence; Antineoplastic Agents; Blood Platelets; Cloning, Molecular; Enzyme Inhibitors; | 2000 |
[Oral chemotherapeutic agents: the roles in cancer chemotherapy].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 1999 |
Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers.
Topics: Animals; Antiviral Agents; Arabinofuranosyluracil; Dioxolanes; Hepatitis B virus; Herpesvirus 4, Hum | 2001 |
Radioactive nucleic acids-precursors: their potential value as tumor-localizing agents.
Topics: Animals; Carcinoma, Hepatocellular; Deoxyuridine; DNA; Iodine Radioisotopes; Leukemia, Lymphoid; Liv | 1977 |
Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients.
Topics: Humans; In Vitro Techniques; Neoplasms; Pentosyltransferases; Thymidine; Thymidine Phosphorylase; Th | 1977 |
[Report on nationwide pooled data and cohort investigation in UFT phase II study].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1987 |
[Study on the preoperative adjuvant therapy of cancer--relation between serum and tumor tissue levels of UFT and OK-432 after administration, and skin reactions to Su-polysaccharide (Su-Ps)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Products; | 1987 |
[Effects of OK-432 on UFT activation].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Products; | 1988 |
Report on nationwide pooled data and cohort investigation in UFT phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Compounding; Drug Evaluation; Humans; Neoplasms | 1988 |
Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
Topics: Aged; Body Temperature; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Paren | 1986 |
Enzymes of uracil catabolism in normal and neoplastic human tissues.
Topics: Amidohydrolases; beta-Alanine; Dihydrouracil Dehydrogenase (NAD+); Fluorouracil; Humans; Kinetics; N | 1985 |
Flexibility of nucleic acid bases and its possible relationship with carcinogenesis.
Topics: Adenine; Animals; Cytosine; DNA; Guanine; Humans; Hydrogen Bonding; Neoplasms; Nucleic Acid Conforma | 1985 |
Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.
Topics: Chromatography, High Pressure Liquid; Deoxyuridine; Humans; Idoxuridine; Infusions, Parenteral; Neop | 1985 |
[Molecular basis of radiosensitization].
Topics: Bromouracil; Chromosome Aberrations; DNA; DNA Repair; Humans; Neoplasms; Radiation Effects; Radiatio | 1972 |
Quantitative analysis of the mechanism of glucocorticoid enhancement of experimental metastasis.
Topics: Animals; Cell Transformation, Neoplastic; Cells, Cultured; Glucocorticoids; Iodine Isotopes; Lung; L | 1972 |
Sponges, cancer chemotherapy, and cellular aging.
Topics: Bacteriological Techniques; Cytarabine; DNA; Escherichia coli; Neoplasms; Nucleosides; Phosphates; P | 1963 |
[Experiences with individual cytostatic therapy of malignant tumors following pretherapeutic sensitivity test to cytostatics in vitro (oncobiogram)].
Topics: Breast Neoplasms; Cell Biology; Culture Techniques; Depression, Chemical; Female; Humans; Lymphoma, | 1970 |
[The hypoplastic state of hematopoiesis following chemotherapy with alkylating compounds].
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Female; Hematologic Disease | 1969 |
Synthesis and oncogenicity of 3-hydroxyuric acid.
Topics: Animals; Benzyl Compounds; Carbon Isotopes; Carcinogens; Chemical Phenomena; Chemistry; Chromatograp | 1971 |
Determination of labile trifluoromethyl compounds with a fluoride--ion electrode: differential analysis of 5-trifluoromethyluracil and 5-trifluoromethyl-2'-deoxyuridine.
Topics: Carbon Isotopes; Chemical Phenomena; Chemistry; Electrodes; Fluorides; Fluorine; Humans; Hydrogen-Io | 1969 |
[Effect of 6-azauridine on serum proteins in patients with advanced neoplastic disease].
Topics: Blood Proteins; Blood Sedimentation; Humans; Iron; Neoplasms; Triazines; Uracil | 1968 |
[Contribution to the problem of distribution of 6-azauracil riboside in the human organism].
Topics: Extracellular Space; Humans; Neoplasms; Ribose; Triazines; Uracil | 1968 |